TACE plus lenvatinib versus lenvatinib alone for unresectable liver cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional comparison enrolls adults aged 18–75 with untreated, measurable unresectable HCC across BCLC stages A–C and ECOG 0–2. Participants receive either transarterial chemoembolization plus oral lenvatinib or lenvatinib monotherapy in a real-world, single-center setting. Tumor response will be measured radiologically using modified RECIST (mRECIST) criteria to compare outcomes between the two groups. The design reflects resource-limited clinical practice where TACE availability can be constrained and aims to see if adding locoregional therapy improves response over systemic therapy alone.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age 18-75 years,
2. Hepatocellular carcinoma, confirmed by dynamic CT scan / MRI or histopathology, consistent with early (stage A), Intermediate (Stage B), subgroup B, and Advanced (stage C) according to BCLC criteria 2022, without a history of any previous treatment,
3. At least one measurable lesion based on mRECIST criteria,
4. ECOG performance status 0-2,

Exclusion Criteria:

1. Diffuse bi-lobar or multi nodular HCC (more than 10 nodules) with more than equal 50% liver involvement,
2. Hepatocellular carcinoma with main trunk portal vein thrombosis,
3. Child Turcotte Pugh Score 10 ( C) or more,
4. ALBI grade 3,
5. Hepatocellular carcinoma with uncontrolled hypertension, recent myocardial infarction, or other thromboembolic event,
6. Known allergy or intolerance to lenvatinib .

Where it's running

• Department of Hepatology, Bangladesh Medical University
  Dhaka, Bangladesh Recruiting

Study contacts

• Principal investigator: Sourav Kumar Chakraborty
• Study coordinator: Sourav Kumar Chakraborty
• Email: drsouravhepato@gmail.com
• Phone: +8801747473455

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Lenvatinib and Pembrolizumab With or Without SBRT for Metastatic Kidney Cancer

  This study tests whether adding SBRT to standard lenvatinib plus pembrolizumab helps people with metastatic kidney cancer who have stable disease after initial treatment.

  Recruiting at 8 sites Phase 2 Kidney Cancer Research Bureau · Kazan' and 7 other locations · NCT07928167

• Cadonilimab and Lenvatinib in advanced kidney cancer

  This study tests whether Cadonilimab plus Lenvatinib can help adults with unresectable, advanced renal cell carcinoma, especially clear cell type, after prior treatments.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Panjiayuan Nanli · NCT07909265

• MRG003 added to ongoing treatment after progression in EGFR-positive advanced thyroid cancer

  In this study, researchers test whether adding MRG003 to a patient’s current thyroid cancer treatment can shrink tumors for those whose cancer initially responded but later progressed.

  Recruiting Phase 2 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07874321

• Cryoablation with liver-directed immunotherapy and targeted therapy for melanoma liver metastases

  This trial tests a combination therapy including cryoablation, hepatic artery delivery of QL1706, intravenous dacarbazine, and oral lenvatinib to treat liver metastases from malignant melanoma in adults.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07847359

• BGB-B2033 vs Sorafenib or Lenvatinib for advanced liver cancer

  This study tests whether the investigational drug BGB-B2033 can help people with advanced hepatocellular carcinoma when given after prior PD-1/PD-L1 therapy, compared with the standard medicines sorafenib or lenvatinib.

  Recruiting at 2 sites Phase 3 BeOne Medicines · South Brisbane, Queensland and 1 other locations · NCT07836530

• Lenvatinib plus chemotherapy for pancreatic neuroendocrine tumors with liver metastases

  This study tests whether adding lenvatinib to chemotherapy helps people with pancreatic neuroendocrine tumors that have spread to the liver, after first-line therapy has stopped working.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT07835893

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.